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Background: During the disease course of high-grade glioma (HGG) patients, the goal of
therapy eventually shifts from primarily life-prolongation to primarily sustaining the qual-
ity of life as good as possible. End-of-life care is aimed at prolongation of life with good
quality, but inevitably also may require medical decisions for prevention and relief of suf-
fering with a potential life shortening effect. Few data are available on this end-of-life deci-
sion (ELD) making process in HGG patients, with decreased consciousness, confusion or
cognitive deficits preventing them to participate. In this study the ELD-making process in
HGG patients is described.
Methods: Physicians and relatives of a cohort of 155 deceased HGG patients were identified
to fill in a questionnaire regarding the end-of-life conditions (patients’ ELD preferences,
patients’ competence) and ELD-making (forgoing treatment and the administration of
drugs with a potential life-shortening effect) for their patient or relative. Data were ana-
lysed with descriptive statistics.
Findings: Of 101 patients, physicians completed surveys including questions about ELDs
(62% response rate). More than half of the patients relatively early became incompetent
to make decisions due to delirium, cognitive deficits and/or decreasing consciousness. In
40% of patients the physician did not discuss ELD preferences with his/her patient. At least
one ELD was made in 72% of patients, most often this comprised the withdrawal of dexa-
methasone. Palliative sedation was performed in 30% of patients and physician assisted
death in 7%.
Interpretation: ELDs are common practises amongst HGG patients, although their prefer-
ences towards ELDs are frequently unknown to the physician. Because the majority of
patients become incompetent towards death, participation in ELD-making is only possible
with advanced care planning. Hence, timely discussion of ELD preferences is encouraged.
 2011 Elsevier Ltd.Open access under the Elsevier OA license. nt of Neurology, VU University Medical Centre, P.O. Box 7057, 1007 MB, Amsterdam,
31 2044 42800.
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High grade gliomas (HGG) are the most frequently occurring
primary malignant brain tumours. Despite intensive treat-
ment with surgery, radiotherapy and chemotherapy, patients
with HGG cannot be cured from this disease and the progno-
sis is poor. Median survival ranges from less than one to more
than 5 years depending on histological subtype, tumour
grade, age and performance status at time of diagnosis.1,2
Inevitably, the end-of-life phase will come when tumour
directed treatment is no longer possible and the patient’s con-
dition declines. During this end-of-life phase, symptom bur-
den will increase and in the end become high. Disease
specific symptoms such as focal neurological deficits, head-
ache, epileptic seizures, confusion and cognitive deficits pre-
vail.3–6 In most patients, intracranial pressure gradually
increases towards death resulting in headache and progres-
sive loss of consciousness.3,5 End-of-life care is aimed at
maintaining quality of life as long as possible, but also may
require medical end of life decisions (ELDs) for the prevention
and relief of suffering: in some instances these decisions may
hasten death.
In our definition, ELDs include the withholding or with-
drawing of life-prolonging treatment, and the administration
of drugs with a potential or certain life-shortening effect.
Examples of ELDs in HGG patients are withdrawal of chemo-
therapy or dexamethasone, withholding artificial food and
fluid administration, non-admittance to the hospital or inten-
sive care unit for treatment of infections, and palliative seda-
tion.7 A large European study revealed that 23–51% of all
deaths are preceded by an ELD depending on the cultural
and legal background.8 In the Netherlands 44% of deaths are
preceded by an ELD.9 In some European countries (The Neth-
erlands, Belgium, and Luxemburg), physician-assisted death
such as euthanasia or physician-assisted suicide are allowed
under strict conditions upon a well considered request.
Until date, little data are available onELDdecision-making in
HGG patients. It can behypothesised that discussing end-of-life
issues with HGG patients becomes progressively more difficult
during the course of their disease because of cognitive distur-
bances, confusion and decreasing consciousness.10 Therefore,
it has been suggested that advance care planning (ACP) should
be encouraged early in the course of the disease.10,11
The aim of this study is to document to what extent HGG
patients expressed wishes regarding end-of-life treatment,
whether thesewisheswere lived up to, and to what extent pa-
tients were able to participate in ELD-making. In addition, we
specifically focused on the patients’ competence in cases
where euthanasia was discussed, a procedure restricted to
fully competent patients. Finally, the nature and frequency
of ELDs made in HGG patients are described.
2. Patients and methods
2.1. Subjects
A retrospective descriptive study was performed sending
questionnaires to physicians and relatives of deceased HGGpatients from a cohort of adult HGG patients diagnosed in
2005 and 2006 in three tertiary referral centres for brain tu-
mour patients (VU University Medical Centre and Academic
Medical Centre Amsterdam Amsterdam, Medical Centre
Haaglanden The Hague, The Netherlands). The physicians in-
volved in end-of-life care of deceased patients of the cohort
were approached for participation in the study. Participating
physicians were asked to fill in a questionnaire regarding
the end-of-life phase of the specific patient. If more than
one physician was involved in end of life care for a specific pa-
tient (for example due to a transition in health care setting
close before death), all physicians were approached for partic-
ipation in the study. The closest relative of the deceased pa-
tient was identified by the physician who was involved in
the end-of-life care or was retrieved from the medical chart.
Identified relatives received a letter shortly explaining the
aim of the study andwere asked to send back a response form
either allowing the researchers to further inform and contact
him/her or declining any interest in participation. Relatives
who allowed to be further informed received a questionnaire
about the end-of-life phase of the deceased patient. The study
protocol was approved by the Ethics Committee of the three
participating hospitals and informed consent was obtained
from all participating relatives.
2.2. Development of questionnaires
The questionnaire for physicians was developed using exist-
ing questionnaires developed in end-of-life research.7,9,12
Questions were related to the last 3 months before death,
and more specifically to the last week before death. The ques-
tionnaire was piloted in interviews with eight physicians: five
general practitioners (GP), two nursing home doctors, and one
neurologist. We adjusted the questionnaire according to the
feedback gained in these interviews.
The questionnaire for relatives was developed along exist-
ing questionnaires regarding quality of life and advance care
planning.13,14 The questionnaire was piloted in five relatives
with face-to-face interviews (two partners, one parent and
two children of the deceased patients). The questionnaire
was adjusted according to the feedback gained in these inter-
views. Questions were related to both the last 3 months and
the last week before death.
2.3. Content of the questionnaires
The questionnaire for physicians comprised both open-ended
and discrete questions and addressed to whether the physi-
cian discussed end-of-life preferences with the patient and
what these preferences were; until what moment the patient
was competent to decide on care and treatment and – if the
patient was incompetent to decide – what the reason for this
incompetence was. Furthermore, ELDs were enquired after
via four core questions: (1) whether the physician had with-
held any life-sustaining treatment, (2) had withdrawn any
life-sustaining treatment, (3) had performed palliative seda-
tion (defined as continuous and deep sedated or kept in
coma), (4) had carried out euthanasia or physician-assisted–
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shortened as a result of the previously described ELD was en-
quired after separately.
The questionnaire for relatives comprised both open-
ended and discrete questions and addressed whether the pa-
tient had an advance directive (AD) regarding ELDs, and
whether the patient had ever expressed a wish for euthana-
sia. The relative should also indicate if any decisions were
made in contradiction with the patient’s or relative’s wishes.
2.4. Statistical analysis
SPSS software 15.0 was used for statistical analysis. Baseline
characteristics and incidences were analysed by means of
descriptive statistics. Chi square tests and T-tests were used
to test differences in baseline characteristics between the
studied patients and other patients in the cohort.Patients diagnosis 
HGG 
(n=223) 
Deceased patients 
(n=155) 
No
•
•
•
Physicians 
(n=155) 
Not approached (n=9) 
• Physician retired (n=3) 
• Physician not traceable 
(n=6)
Physicians 
approached 
(n=146) 
Physicians 
participated 
(n=106) 
Declined (n=40) 
• Lack time/ no interest 
(n=37) 
• Could not recall (n=3) 
Excluded from analysis 
(n=5) 
• Data ELD not complete 
(n=5)
Data physician 
analyzed 
(n=101) 
Fig. 1 – Identificati3. Results
3.1. Subjects
Fig. 1 shows the flow chart of patient identification and data
collection. Of 101 patients, data on ELDs provided by the phy-
sician were complete (62% response rate). Additionally, of 50
of these 101 patients’ data from relatives were available.
The physician responsible in the last week of life was a GP
in 71 cases (70%), a nursing home specialist in 21 cases (21%)
and a clinical specialist in nine cases (9%). As stated before, in
50 of these 101 patients, a relative participated in the study as
well. The relatives’ relation to the deceased patient was part-
ner in 41 cases (82%), parent in three cases (6%), child in five
cases (10%) and sibling in one case (2%).
Patient characteristics of our cohort are outlined in Table 1.
The 155 patients eligible for inclusion in the study were sig-t eligible (n=68) 
 Patient still alive (n=39) 
 Emigration (n=4) 
Not traceable (n=25)
Relatives 
(n=155) 
Not approached (n=24) 
• No contact information 
(n=17)  
• Relative died (n=4) 
• GP advised against (n=3) 
Relatives  
approached 
(n=131) 
Declined (n=48) 
• No response (n=23) 
• Too burdensome (n=20) 
• Lack time/ no interest 
(n=3)
Relatives 
participated 
(n=83) 
Excluded from analysis (n=33) 
• Physician data ELD not 
complete (n=33)
Data relatives 
analyzed 
(n=50) 
on of subjects.
Table 1 – Patient characteristics.
Patient characteristics Cohort (n = 223)
Overall (n = 223) Eligible for inclusion (n = 155)
All patients eligible
for inclusion (n = 155)
Included in analysis (n = 101)
Overall
(n = 101)
Physician data
only (n = 51)
Physician and
relatives data (n = 50)
Sex
Male 63% 68% 72% 70% 75%
Female 37% 32% 28% 30% 25%
Age at diagnosis, yearsa 57 60 60 58 59
Tumour grade
Grade 3 20%* 11%* 12% 10% 14%
Grade 4 80%* 89%* 88% 90% 86%
Place of death
At home NA 64% 66% 72% 60%
Nursing home NA 16% 15% 16% 14%
Hospital NA 7% 8% 4% 12%
Hospice NA 10% 8% 6% 10%
Other NA 3% 3% 2% 4%
a Mean.
* Significant difference, p = 0.023.
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(p = 0.023) as compared to all 223 patients of the cohort. There
were no significant differences in patient characteristics be-
tween the 101 patients analysed in this study and the 155 pa-
tients eligible for inclusion, nor between the 50 patients of
whom the relatives participated in the study and the 51 pa-
tients in whom no relatives’ data were obtained.Incompetent
Competent3.2. End-of-life preferences and competence
The physicians of 61 patients (60%) were aware that their pa-
tient had ELD preferences. In 58 patients, the physician dis-
cussed these wishes with the patient and in three patients,
the physician had been informed in another way. In threeTable 2 – Type of end of life preferences expressed by the
patient according to physician (n = 101).
Any wishes expressed 60%
Specific wishes*:
Life prolonging treatment
In favour 2%
Opposed 36%
No opinion/not discussed 62%
Admission to hospital
In favour 4%
Opposed to 45%
Not discussed/no opinion/not applicable 51%
Palliative sedation
In favour 24%
Opposed to 5%
Not discussed/no opinion 71%
Euthanasia
In favour 18%
Opposed to 20%
Not discussed/no opinion 62%
* Multiple wishes per patient possible.other patients (3%), the physician initiated a discussion
regarding ELD preferences, but the patient did not express
preferences or declined to discuss ELD preferences. In Table 2,
the specific ELD preferences known by the physician are
displayed.
GPs more frequently discussed ELD preferences with the
patient in comparison to physicians working in an institution:
73% of GPs compared to 40% of nursing home specialists and
22% of clinical specialists respectively (p = 0.001).
Fig. 2 displays until what time point before death the pa-
tient was deemed competent to participate in decision-mak-0
10
20
30
40
50
60
70
80
90
100
last months before
death
last weeks before
death
last days before
death
Fig. 2 – Proportion of patients competent to participate in
end of life decision-making at various time points before
death (n = 101; physician data).
Table 3 – End of life decisions in the cohort (n = 101;
physician data).
Number of patients (%)
No ELDs 28 (28)
Any ELD 73 (72)
Specific ELDs*
Withhold treatment 29 (29)
Withdraw treatment 56 (55)
Palliative sedation 30 (30)
Physician assisted death 7 (7)
Life shortening effect of ELDs
Not applicable 28 (28)
No 43 (43)
Hours 10 (10)
Days 12 (12)
Week or more 8 (8)
* Multiple ELDs per patient possible.
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incompetent to assess their own situation in the last weeks
of life due to: cognitive disturbances in 31 patients, somno-
lence in 26, aphasia in 16 and/or delirium in 12 patients. An-
other 33 (33%) patients lost their competence during the last
week of life, most often as a result of decreasing conscious-
ness. Patients who died in an institution were incompetent
in an earlier stage than the patients who died at home.
3.3. End-of-life decisions (ELDs)
From 72% of patients, the physician indicated that at least one
ELD was made (Table 3). Withholding treatment was decided
on in 29 patients (29%) and concerned the withholding of: (a)
antibiotic treatment for an infection (eleven patients), (b)
artificial administration of food and fluids (nine patients), (c)
admission to the hospital for treatment (six patients), (d)
administration of dexamethasone (three patients), (e)
planned radiotherapy (two patients), and (f) placement of a
ventricular drain (one patient). In 56 patients (55%), one or
several treatments were withdrawn in the end-of-life phase.
This comprised the withdrawal of: (a) dexamethasone (51
patients), (b) temozolomide chemotherapy (two patients), (c)
antibiotic drugs (one patient), (d) insulin (one patient) and
(e) the artificial administration of fluids (one patient).
For thirty patients (30%), the physician indicated that pal-
liative sedation had been carried out. In 27 of these patients,
benzodiapines were administered and three patients were se-
dated with opioids. The start of sedation ranged from several
days to several hours before death.
According to the physician, ten patients requested eutha-
nasia. In seven cases, this request was granted and euthana-
sia was performed in a stage of the disease where the patient
was completely able to judge his own situation. In two of the
ten patients, the request was not granted because the patient
was unable to decide as a result of cognitive deficits and delir-
ium. In one of these patients, palliative sedation was started,
in the other patient no ELDs were applied. In one patient,
euthanasia was not carried out as the patient withdrew the
request for euthanasia. In this patient, palliative sedation
was eventually started close before death.In 30 patients (30%), the physician indicated the patient’s
life was probably shortened because of ELDs made (Table 3).
3.4. End-of-life preferences according to relatives
Of the 50 patients of whom data of both their physician and
relatives was available, data regarding expressed preferences
were correlated. According to their relatives, 21 patients (42%)
had an advance directive (AD). Physicians of 12 of these pa-
tients were aware of the AD, five other physicians discussed
wisheswith the patient, but were unaware of the AD, and four
physicians were unaware of any preferences of the patient. In
13 of the 21 patients, the AD concerned a wish for euthanasia.
According to the answers of the relatives, 19 of the 50
patients (38%) ever expressed a wish for euthanasia to be
carried out under certain circumstances. In 11 of these 19
patients, the wish never became active or the patient died
before the procedure could be discussed. In the other eight
cases, euthanasia was discussed in the end-of-life phase.
According to the physician, four of these eight patients even-
tually requested euthanasia, which was granted. In the other
four patients, the patient’s wish was discussed, but could not
be granted as the patient had become incompetent due to
cognitive deficits (three patients) and decreased conscious-
ness (one patient). In these four patients other ELDs were
made: in two patients, the physician withdrew dexametha-
sone treatment and started palliative sedation, in one patient
the physician withdrew dexamethasone treatment and with-
held artificial administration of fluids, and in the remaining
patient, the physician withheld antibiotic treatment whilst
the patient had pneumonia.
Relatives of six patients were dissatisfied because deci-
sions were made against the patient’s wishes. In two cases,
this concerned not performing euthanasia because the pa-
tient had become incompetent (in one of these patients, the
patient had a written AD requesting euthanasia in case of a
declining condition), in two cases the patient had to be admit-
ted to an institution in the end-of-life phase, in one case, the
physician started artificial administration of fluids and nutri-
ents despite a refusal of treatment, and in one case, the phy-
sician had withdrawn all medication including anti-epileptic
drugs, causing seizures in the end-of-life phase.4. Discussion
In this study, end of life data were obtained from a represen-
tative sample of physicians and relatives of a cohort HGG pa-
tients. We have shown that in 40% of patients, physicians
were unaware of the patients’ end of life preferences, even
though several patients had an AD according to their rela-
tives. About half of the patients had become incompetent to
participate in ELD-making before the last week of life. In
approximately three quarters of HGG patients ELDs were
carried out. Palliative sedation was performed in 30% of all
patients and euthanasia in 7%.
To our knowledge, this is the first study systematically
evaluating decision-making and end-of-life practices in HGG
patients. The response rate was high in comparison to ELD
studies in other diseases and the eligible patients are largely
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ing both the physicians’ and the relatives’ perspective adds
on to the strength of our study.
Physicians discussed ELD preferences with HGG patients
less often than reported in other cancer patients.15 Probably
physicians postpone discussing ELDs until the last week be-
fore death.15 By that time, however, the large majority of
HGG patients have become incompetent to participate in
ELD discussions. Moreover, the physicians’ estimation that
20% of patients are incompetent in the last months before
death is probably an underestimation. A previous study eval-
uating competence in high grade glioma patients median
4 months after diagnosis found that 15–23% of patients were
incapable to decide.16 Since most cancer patients wish to be
involved in decision-making at the end-of-life, our results
underscore that ELD-making for HGG patients warrants
improvement.17 Timely organisation of ACP could contribute
to improve ELD-making.10 The aim of ACP is to reach consen-
sus about possible ELDs between all participants, respecting
both patients’ and families’ values.18 Given the fact that in
the large majority of HGG patients ELD-making becomes an
issue, ACP should become standard for HGG patients. Physi-
cians should discuss the patients’ preferences relatively soon
after diagnosis, and repeat this discussion subsequently.
A study evaluating ACP in HGG patients during treatment
showed that the majority of patients is willing to discuss po-
tential end-of-life scenarios and – once the various treatment
options are clear – the majority preferred comfort care over
life-prolonging treatment.19
Unfortunately, according to this study, ACP is not always
effective. In 40% of patients the physicians were unaware of
the patients’ AD and not all expressed wishes can be lived
up to. Clear communication with patients and – especially
when the patient has become incompetent – their relatives
are of major importance.18
A minority of patients, however, are unwilling to discuss
ELD. In our cohort, at least 3% and in the previously men-
tioned study into ACP, 12% of patients were unwilling to dis-
cuss this topic.19
The most frequently reported ELD in our study was with-
drawal of dexamethasone close before death, as has been re-
ported in previous studies on this issue.5,6 The incidence of
palliative sedation as ELD in our study is high: 30% of patients
received palliative sedation with sedative drugs, which is
more than twice as high as has been reported in an Italian
HGG population.6 In comparison, in the general Dutch
mortality figures, 13% of non-sudden deaths was preceded
by palliative sedation.9 The main reason for palliative seda-
tion in terminal patients is delirium and agitation.20 We
hypothesise that the high incidence of palliative sedation in
our study may be explained by the high incidence of confu-
sion in HGG patients. Unfortunately, however, we did not spe-
cifically explore the reason for starting palliative sedation.
Euthanasia had eventually been carried out in 7% of pa-
tients. This percentage appears to be relatively high in com-
parison with non-sudden deaths in the general Dutch
population (2.7%)9 and comparedwith Belgian cancer patients
(4.6%) (a country with comparable legislation).21 In patients
with amyotrophic lateral sclerosis (ALS), a neurological condi-
tion with a similar poor prognosis as HGG patients, however,the proportion of patients in whom euthanasia is performed
is far higher (16.8%).22,23 In at least six of our cases, the patient
explicitly expressed a wish for euthanasia which could not be
granted because the patient had become incompetent. It can
be implied that the procedure for euthanasia is relatively of-
ten hampered in HGG patients due to the patients’ incompe-
tence to assess their own situation towards death as a result
of cognitive disturbances, delirium and decreasing conscious-
ness, which is generally not the case in ALS patients.
Our study has some limitations. As we selected deceased
patients after a prefixed interval from a cohort diagnosed
within a two-year frame there is a bias towards patients with
relatively short disease duration, i.e. glioblastoma patients.
Another limitation is the fact that patients’ physicians and
relatives answered the questions regarding the patients retro-
spectively with a relatively long interval since the patients’
death, possibly causing recall bias. Although this is a common
and generally acknowledged practice in end-of-life re-
search,24 the results should be interpreted with caution. Fur-
thermore, the estimation of how long a patient might have
lived if ELDs had not been carried out is a subjective measure
as this is difficult to estimate in any circumstance. Studies
have shown that survival of patients receiving palliative seda-
tion is not significantly different from patients who were not
given sedatives and one study even found a longer survival in
patients receiving sedation.25
Overall, it can be concluded that ELDs are very common
practices in HGG patients. As most patients become incompe-
tent as death approaches, the decision-making process is not
always straightforward. Physicians caring for HGG patients in
the end-of-life phase should discuss the full spectrum of ELD
preferences before the patient becomes incompetent. Guide-
lines should be developed to facilitate timely discussion of
ACP in HGG patients. Furthermore, as cultural and legal as-
pects of ELDs vary amongst countries and cultures, it would
be very interesting to compare ELD practices in HGG patients
between various countries and cultures.
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